S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
OTCMKTS:IPCIF

Intellipharmaceutics International (IPCIF) Stock Price, News & Analysis

$0.07
+0.01 (+18.68%)
(As of 03/28/2024 ET)
Today's Range
$0.07
$0.07
50-Day Range
$0.03
$0.08
52-Week Range
$0.00
$0.11
Volume
103 shs
Average Volume
6,643 shs
Market Capitalization
$2.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IPCIF stock logo

About Intellipharmaceutics International Stock (OTCMKTS:IPCIF)

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.

IPCIF Stock Price History

IPCIF Stock News Headlines

Intellipharmaceutics International Inc. (IPCI.TO)
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
IPCIF Intellipharmaceutics International Inc.
Intellipharmaceutics Announces Cease Trade Order
Intellipharmaceutics Announces Third Quarter 2022 Results
Intellipharmaceutics Announces Fiscal Year 2021 Results
Intellipharmaceutics Comments on Recent Trading Activity
See More Headlines
Receive IPCIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellipharmaceutics International and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/16/2018
Today
3/29/2024
Next Earnings (Estimated)
6/03/2024
Fiscal Year End
11/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:IPCIF
Employees
11
Year Founded
N/A

Profitability

Net Income
$-2,890,000.00
Net Margins
-344.25%
Pretax Margin
-343.61%

Debt

Sales & Book Value

Annual Sales
$660,000.00
Book Value
($0.32) per share

Miscellaneous

Free Float
32,511,000
Market Cap
$2.35 million
Optionable
Not Optionable
Beta
1.00
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Isa Odidi MBA (Age 66)
    Ph.D., Co-Founder, Chairman of the Board, CEO & Co-Chief Scientific Officer
    Comp: $347.94k
  • Dr. Amina Odidi Ph.D. (Age 64)
    President, COO, Co-Chief Scientific Officer, Acting CFO & Executive Director
    Comp: $347.94k
  • Dr. Patrick N. Yat Ph.D. (Age 66)
    Vice-President of Chemistry & Analytical Services
    Comp: $119.93k
  • Fazayill Shaideen
    Controller

IPCIF Stock Analysis - Frequently Asked Questions

How have IPCIF shares performed in 2024?

Intellipharmaceutics International's stock was trading at $0.0642 at the beginning of 2024. Since then, IPCIF stock has increased by 10.8% and is now trading at $0.0712.
View the best growth stocks for 2024 here
.

Are investors shorting Intellipharmaceutics International?

Intellipharmaceutics International saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,000 shares, an increase of 100.0% from the February 29th total of 500 shares. Based on an average daily volume of 4,400 shares, the days-to-cover ratio is presently 0.2 days.
View Intellipharmaceutics International's Short Interest
.

When is Intellipharmaceutics International's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, June 3rd 2024.
View our IPCIF earnings forecast
.

How were Intellipharmaceutics International's earnings last quarter?

Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) released its quarterly earnings data on Monday, July, 16th. The company reported ($0.70) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.70). The business earned $0.58 million during the quarter, compared to analysts' expectations of $0.90 million.

When did Intellipharmaceutics International's stock split?

Shares of Intellipharmaceutics International reverse split on Friday, September 14th 2018. The 1-10 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Intellipharmaceutics International?

Shares of IPCIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IPCIF) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners